Genscript Biotech (HK:1548) has released an update.
Genscript Biotech’s subsidiary, Legend Biotech, has reported positive results from its Phase 3 CARTITUDE-4 trial, demonstrating a significant improvement in overall survival rates for patients with relapsed and lenalidomide-refractory multiple myeloma. The trial compared CARVYKTI, a therapy developed by Legend Biotech, to other treatments, showing not only efficacy but also a consistent safety profile with no new concerns. Investors are encouraged to consider these developments carefully due to their potential impact on investment decisions.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
